Pulmonary Arterial Hypertension (pah) Clinical Trials
2 recruiting trials for Pulmonary Arterial Hypertension (pah). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Pulmonary Arterial Hypertension (pah) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
The only sponsor on record for these trials is University of Sao Paulo General Hospital (2 trials).
The most frequently studied intervention is Application of Patient Knowledge Questionnaire on Pulmonary Hypertension (other, 1 trial), followed by There will be no intervention.
Track Pulmonary Arterial Hypertension (pah) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension
This methodological study aims to develop and validate a questionnaire named for the Assessment of Patient Knowledge in Pulmonary Arterial Hypertension. The study will be...
PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study \--- Pulmonary arterial hypertension (PAH)...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Pulmonary Arterial Hypertension (pah), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Pulmonary Arterial Hypertension (pah), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Pulmonary Arterial Hypertension (pah), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.